[go: up one dir, main page]

CO2020000369A2 - Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos - Google Patents

Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos

Info

Publication number
CO2020000369A2
CO2020000369A2 CONC2020/0000369A CO2020000369A CO2020000369A2 CO 2020000369 A2 CO2020000369 A2 CO 2020000369A2 CO 2020000369 A CO2020000369 A CO 2020000369A CO 2020000369 A2 CO2020000369 A2 CO 2020000369A2
Authority
CO
Colombia
Prior art keywords
fusion proteins
modified polypeptides
polypeptides
serum albumin
complement component
Prior art date
Application number
CONC2020/0000369A
Other languages
English (en)
Inventor
Douglas L Sheridan
Paul P Tamburini
Bridget Puffer
Julian Chandler
Nimish Gera
Siddharth Jindal
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of CO2020000369A2 publication Critical patent/CO2020000369A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

RESUMEN La descripción proporciona polipéptidos modificados que se unen específicamente al componente del complemento humano C5 y/o albúmina sérica. La descripción también proporciona proteínas de fusión que comprende esos polipéptidos modificados, donde esas proteínas de fusión pueden ser proteínas de fusión multivalentes o multiespecíficas. La descripción proporciona además moléculas de ácido nucleico que codifican para esos polipéptidos modificados o proteínas de fusión y métodos para producir esos polipéptidos modificados o proteínas de fusión. La descripción proporciona además composiciones farmacéuticas que comprenden esos polipéptidos modificados o proteínas de fusión y métodos de tratamiento usando esos polipéptidos modificados o proteínas de fusión.
CONC2020/0000369A 2017-07-11 2020-01-15 Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos CO2020000369A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531215P 2017-07-11 2017-07-11
PCT/US2018/041661 WO2019014360A1 (en) 2017-07-11 2018-07-11 POLYPEPTIDES BINDING COMPONENT C5 OR SERUM ALBUMIN COMPONENT AND FUSION PROTEINS THEREOF

Publications (1)

Publication Number Publication Date
CO2020000369A2 true CO2020000369A2 (es) 2020-01-31

Family

ID=63036501

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0000369A CO2020000369A2 (es) 2017-07-11 2020-01-15 Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos

Country Status (12)

Country Link
US (3) US11498960B2 (es)
EP (1) EP3625265A1 (es)
JP (3) JP7684803B2 (es)
KR (3) KR102806328B1 (es)
CN (3) CN117327188A (es)
AU (3) AU2018301412B2 (es)
BR (1) BR112019028269A2 (es)
CA (1) CA3067247A1 (es)
CO (1) CO2020000369A2 (es)
IL (3) IL307197B1 (es)
MX (2) MX2024005945A (es)
WO (1) WO2019014360A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067247A1 (en) 2017-07-11 2019-01-17 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
US20210388070A1 (en) * 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
JP2022529264A (ja) * 2019-04-16 2022-06-20 ユニバーシティ オブ ワシントン アマンタジン結合タンパク質
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN114867484B (zh) 2019-12-26 2024-08-06 卫材R&D管理有限公司 含有抑制补体c5的表达的双链核糖核酸的药物组合物
WO2021144962A1 (ja) 2020-01-17 2021-07-22 オリンパス株式会社 発光装置、および駆動装置
EP4135837A1 (en) 2020-04-16 2023-02-22 Assistance Publique, Hopitaux De Paris Methods for treating a complement mediated disorder caused by viruses
EP4225372A4 (en) * 2020-10-05 2024-11-06 Alexion Pharmaceuticals, Inc. Methods of treating dermatomyositis
EP4580749A1 (en) * 2022-08-31 2025-07-09 Alexion Pharmaceuticals, Inc. Dosage and administration of fusion polypeptides for treatment of sickle cell disease
CN116731149B (zh) * 2023-06-07 2024-02-27 华中农业大学 草鱼补体活化分子碳末端肽C5a-CP及应用
CN119241699B (zh) * 2024-09-24 2025-11-28 广州康盛生物科技股份有限公司 一种抗人补体c5的单域抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
DE60041564D1 (de) 1999-12-24 2009-03-26 Genentech Inc Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
PT1355919E (pt) * 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
EP1558645B1 (en) * 2002-11-08 2011-07-27 Ablynx N.V. Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
EP2301967A3 (en) 2002-11-08 2011-07-13 Ablynx N.V. Single domain antibodies for nasal administration
NZ540771A (en) 2003-01-10 2009-05-31 Ablynx Nv Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
AU2012254935B2 (en) * 2004-02-12 2014-05-29 Archemix Llc Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
BRPI0511755A (pt) 2004-06-01 2008-01-02 Domantis Ltd composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN100368022C (zh) 2005-09-20 2008-02-13 中国人民解放军第二军医大学 双重靶向抗肝纤维化药物载体拟糖蛋白纳米粒及其制法
AR056138A1 (es) * 2005-10-21 2007-09-19 Hoffmann La Roche Procedimiento para la expresion recombinante de un polipeptido
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
EP2262831B1 (en) 2008-03-03 2015-01-21 NovelMed Therapeutics, Inc. Anti-properdin antibodies
SG10201405377XA (en) * 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
IN2012DN01663A (es) 2009-09-16 2015-06-05 Immunomedics Inc
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011095545A1 (en) * 2010-02-05 2011-08-11 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
EP2545075B1 (en) 2010-03-10 2020-07-01 NovelMed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
ES2676403T3 (es) 2010-07-09 2018-07-19 Affibody Ab Polipéptidos
TW201241008A (en) 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
SG10201703249PA (en) 2011-12-21 2017-05-30 Novartis Ag Compositions and methods for antibodies targeting factor p
EP2797629A4 (en) 2011-12-28 2015-09-30 Novelmed Therapeutics Inc AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
HRP20190522T1 (hr) 2012-02-20 2019-05-03 Swedish Orphan Biovitrum Ab (Publ) Polipeptidi koji se vežu za humani komplement c5
JP2015532303A (ja) 2012-10-04 2015-11-09 ノベルメド セラピューティクス，インコーポレーテッド 溶血性疾患を治療するための補体第２経路特異的抗体
DK3038633T3 (da) 2013-08-28 2021-01-11 Ipc Res Llc Stabile polypeptider der binder til human komplement c5
CN105473606A (zh) 2013-08-28 2016-04-06 阿菲博迪公司 具有突变的支架的结合多肽
NZ631007A (en) * 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US11198725B2 (en) * 2017-01-30 2021-12-14 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
CA3067247A1 (en) 2017-07-11 2019-01-17 Alexion Pharmaceuticals, Inc. Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof

Also Published As

Publication number Publication date
AU2018301412A1 (en) 2020-01-30
AU2025200303A1 (en) 2025-02-13
IL307197B1 (en) 2025-11-01
US11498960B2 (en) 2022-11-15
IL271920A (en) 2020-02-27
JP2023120208A (ja) 2023-08-29
CA3067247A1 (en) 2019-01-17
BR112019028269A2 (pt) 2020-07-14
CN117327188A (zh) 2024-01-02
CN111201246A (zh) 2020-05-26
CN111201246B (zh) 2023-10-27
KR20250068795A (ko) 2025-05-16
US20250163138A1 (en) 2025-05-22
AU2018301412A9 (en) 2025-08-07
RU2020102910A3 (es) 2021-12-02
IL307197A (en) 2023-11-01
WO2019014360A1 (en) 2019-01-17
WO2019014360A8 (en) 2019-02-21
MX2024005945A (es) 2024-06-11
AU2025200313A1 (en) 2025-02-13
KR20200026264A (ko) 2020-03-10
RU2020102910A (ru) 2021-08-11
EP3625265A1 (en) 2020-03-25
IL324119A (en) 2025-12-01
JP7684803B2 (ja) 2025-05-28
US20200399351A1 (en) 2020-12-24
IL271920B1 (en) 2023-11-01
IL271920B2 (en) 2024-03-01
KR20250099285A (ko) 2025-07-01
US20230235033A1 (en) 2023-07-27
MX2024005946A (es) 2024-06-11
AU2018301412B2 (en) 2025-08-07
KR102806328B1 (ko) 2025-05-14
JP2020532285A (ja) 2020-11-12
CN117327187A (zh) 2024-01-02
JP2025118590A (ja) 2025-08-13
US12221473B2 (en) 2025-02-11

Similar Documents

Publication Publication Date Title
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CL2018002694A1 (es) Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112)
CL2018003136A1 (es) Proteínas de unión específica y usos de las mismas.
CL2021000516A1 (es) Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
CO2018003852A2 (es) Proteínas de unión a antigeno que activan el receptor de leptina
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
AR115389A1 (es) Anticuerpo antagonista de cd73
CO2018003863A2 (es) Anticuerpos anti-vegf
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112016015140A2 (pt) imunoglobulina com fabs in-tandem e usos das mesmas
CO2019003951A2 (es) Proteínas de unión a cd123 y composiciones y métodos relacionados
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
CL2018003438A1 (es) Anticuerpos a la alfa-sinucleína y usos de los mismos.
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
BR122020006907B8 (pt) Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
UY36561A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112018072723A2 (pt) composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
BR112019010034A2 (pt) fator viii alvejado de hemácia e método de uso do mesmo